Promomed has announced the launch of Apalutamide-Promomed (apalutamide), the first domestic second-generation androgen receptor inhibitor used to treat both metastatic hormone-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.
The drug was presented to the medical community at the XI St. Petersburg International Oncology Forum White Nights, emphasizing its role as a valuable addition to oncological practice.
According to 2023 data, prostate cancer has become the most common cancer among men in Russia and the third leading cause of cancer-related deaths, the press service of Promomed reports. This was reported by the Promomed’s press service.
Production of the drug is fully localized in Russia at AO Biochemik’s plant, adhering to GMP standards throughout all stages, from substance preparation to packaging.
The drug’s efficacy has been validated through clinical trials. According to the TITAN study, a randomized, double-blind, placebo-controlled phase III trial, the combination of apalutamide with androgen deprivation therapy reduces the risk of death by 35%, marking a significant advancement in the treatment of prostate cancer.
Earlier, the Federal Antimonopoly Service (FAS) of Russia approved the price of the Russian drug Apalutamide-Promomed. The price of a 60 mg tablet is set at 659 rubles, which is 40% lower than the original drug, Erleada (Janssen), priced at 1,176 rubles per tablet.
The Federal Antimonopoly Service believes that lowering costs will increase patients’ access to modern treatments and lessen the financial strain on the compulsory health insurance system.
